Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive Disease and Experience Excellent Five-year Survival without Chemotherapy

First Presentation of Distant Recurrence Data from German PlanB Study Shows Very Low Recurrence Rates at Five Years in Clinically High-risk Patients with Low Recurrence Score® Results and No Chemotherapy